Sugi Predict

Sugi Predict / Compounds / SCHEMBL7146048

SCHEMBL7146048

SCHEMBL7146048

CC#CCN1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.52
▸ RECQL P46063 1/20 0.52
▸ POLB P06746 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GLA P06280 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KEAP1 Q14145 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20047092 1.00 ALDH1A1 (0.52) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL6929250 0.85 POLB (0.59) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL1745361 0.80 ALDH1A1 (0.66) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL12374731 0.79 ALDH1A1 (0.50) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL17392944 0.79 POLB (0.50) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL6930770 0.78 LMNA (0.70) ALDH1A1RECQLPOLBGAAKDM4E
SCHEMBL14083741 0.77 ALDH1A1 (0.43) ALDH1A1RECQLKDM4EHSD17B10GLA
SCHEMBL4011716 0.77 — —
SCHEMBL19886703 0.77 — —
SCHEMBL23085722 0.76 ALDH1A1 (0.47) ALDH1A1RECQLPOLBGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP claimed
EP-1272185-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2003-01-08 — — EP claimed
CN-1371371-A Novel derivatives of flavones, xanthones and coumarins INDENA SPA (IT) 2002-09-25 — — CN claimed
WO-2002002534-A1 QUINAZOLINES WITH THERAPEUTIC USE ASTRAZENECA AB (SE) 2002-01-10 — — WO claimed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 — — WO claimed
WO-2023235433-A1 BICYCLIC INHIBITORS OF IRAK RIGEL PHARMACEUTICALS, INC. (US) 2023-12-07 — — WO disclosed
US-20230322732-A1 RIP1 Inhibitory Compounds and Methods for Making and Using the Same RIGEL PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
US-20230265103-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2023-08-24 — — US disclosed
US-20230057341-A1 HETEROCYCLIC RIP1 KINASE INHIBITORS RIGEL PHARMACEUTICALS, INC. 2023-02-23 — — US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
US-11377428-B2 RIP1 inhibitory compounds and methods for making and using the same RIGEL PHARMACEUTICALS, INC. (US) 2022-07-05 — — US disclosed
US-11370765-B2 RIP1 inhibitory compounds and methods for making and using the same RIGEL PHARMACEUTICALS, INC. (US) 2022-06-28 — — US disclosed
EP-1272185-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2003-01-08 — — EP disclosed
WO-2002002534-A1 QUINAZOLINES WITH THERAPEUTIC USE ASTRAZENECA AB (SE) 2002-01-10 — — WO disclosed
WO-2001066099-A2 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2001-09-13 — — WO disclosed
EP-0929530-A1 QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1999-07-21 — — EP disclosed
CN-1209125-A Piperazine derivatives as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 1999-02-24 — — CN disclosed
CN-1038410-C Butynelamine derivative NIPPON SHINYAKU CO LTD (JP) 1998-05-20 — — CN disclosed
WO-1998013354-A1 QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ZENECA LIMITED (GB) 1998-04-02 — — WO disclosed
CN-1041582-A BUTYNELAMINE DERIVATIVE NIPPON SHINYAKU CO LTD (JP) 1990-04-25 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265103-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 ALDH1A1 4836/4885RECQL 2047/4885POLB 944/4885
US-20230322732-A1 RIP1 Inhibitory Compounds and Methods for Making and Using the Same RIPK1, RIPK2, RIPK3 ALDH1A1 4505/4885RECQL 2238/4885POLB 2900/4885
US-11377428-B2 RIP1 inhibitory compounds and methods for making and using the same RIPK1, RIPK2, RIPK3 ALDH1A1 4505/4885RECQL 2238/4885POLB 2900/4885
US-20230057341-A1 HETEROCYCLIC RIP1 KINASE INHIBITORS RIPK1, RIPK2, RIPK3 ALDH1A1 4559/4885RECQL 2244/4885POLB 3339/4885
US-11370765-B2 RIP1 inhibitory compounds and methods for making and using the same RIPK1, RIPK2, RIPK3 ALDH1A1 4505/4885RECQL 2238/4885POLB 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.